We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+4.59%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$802M
AUM Growth
+$138M
Cap. Flow
+$139M
Cap. Flow %
17.3%
Top 10 Hldgs %
99.69%
Holding
13
New
2
Increased
7
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$39.1M
2
BIIB icon
Biogen
BIIB
+$27.3M
3
AGN
Allergan plc
AGN
+$24.2M
4
MDCO
Medicines Co
MDCO
+$18.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$175M 21.76%
1,042,500
+174,500
+20% +$24.2M
MDCO
2
DELISTED
Medicines Co
MDCO
$153M 19.1%
4,202,000
+566,000
+16% +$18.5M
BIIB icon
3
Biogen
BIIB
$30B
$150M 18.75%
643,000
+118,342
+23% +$27.3M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$696M
$106M 13.25%
9,718,000
+712,613
+8% +$7.98M
INVA icon
5
Innoviva
INVA
$1.55B
$90.9M 11.33%
6,242,000
+215,900
+4% +$3.06M
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$60.2M 7.51%
757,000
+437,000
+137% +$39.1M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.9B
$28M 3.49%
196,500
+96,500
+97% +$13M
PBYI icon
8
Puma Biotechnology
PBYI
$404M
$18M 2.25%
1,417,000
– –
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$15.2M 1.89%
150,000
– –
CYCN icon
10
Cyclerion Therapeutics
CYCN
$14.9M
$2.86M 0.36%
+12,500
New +$3.54M
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$2.31M 0.29%
+185,185
New +$2.13M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$103K 0.01%
1,000
– –
ABBV icon
13
AbbVie
ABBV
$443B
$72K 0.01%
1,000
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sarissa Capital Management held 13 positions worth $802M, up 21% from $664M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $139M of net new capital in Q2 2019, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Cyclerion Therapeutics: 12,500 shares worth $2.86M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier.

  • Sarissa Capital Management's largest Q2 2019 buy was Cyclerion Therapeutics: 12,500 shares worth $2.86M.
  • Sarissa Capital Management added most to Intercept Pharmaceuticals, Inc. in Q2 2019, an estimated $39.1M increase.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $802M portfolio in Q2 2019.
  • Sarissa Capital Management opened 2 new positions and closed 0 in Q2 2019.
  • Sarissa Capital Management's portfolio value rose 21% quarter-over-quarter to $802M.

Based on Sarissa Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.